| 80.37 0.12 (0.15%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 96.03 | 1-year : | 98.64 |
| Resists | First : | 82.22 | Second : | 84.45 |
| Pivot price | 81.07  |
|||
| Supports | First : | 78.59 | Second : | 65.39 |
| MAs | MA(5) : | 79.67 |
MA(20) : | 81.52 |
| MA(100) : | 76.32 |
MA(250) : | 72.51 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.6 |
D(3) : | 15.9 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 84.45 | Low : | 63.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RDY ] has closed above bottom band by 38.4%. Bollinger Bands are 6.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 80.78 - 81.09 | 81.09 - 81.4 |
| Low: | 79.14 - 79.52 | 79.52 - 79.9 |
| Close: | 79.76 - 80.34 | 80.34 - 80.91 |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Fri, 13 Sep 2024
10,202 Shares in Dr. Reddy's Laboratories Limited (NYSE:RDY) Acquired by Natixis Advisors LLC - MarketBeat
Thu, 12 Sep 2024
Dr. Reddy’s Shareholders Approve Stock Split - TipRanks
Thu, 12 Sep 2024
Zacks Research Brokers Lower Earnings Estimates for Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Wed, 11 Sep 2024
13,080 Shares in Dr. Reddy's Laboratories Limited (NYSE:RDY) Bought by Caprock Group LLC - MarketBeat
Tue, 10 Sep 2024
Dr. Reddy’s Laboratories Addresses Allegations - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 17,530 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 1.6659e+008 (%) |
| Held by Institutions | 1.1985e+008 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 7.954e+010 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.9 |
| Profit Margin | 298.7 % |
| Operating Margin | 19.2 % |
| Return on Assets (ttm) | 23.3 % |
| Return on Equity (ttm) | 10.9 % |
| Qtrly Rev. Growth | 2.8851e+011 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 3.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 21 |
| Price to Book value | -89.31 |
| Price to Sales | 6.84257e+010 |
| Price to Cash Flow | 1.40889e+012 |
| Dividend | 2.27e+006 |
| Forward Dividend | 1.94e+006 |
| Dividend Yield | 2824440% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|